GlassScriptPhysician profile
Herve Boucard
NPI 1891764718
$8,282.98
in general payments reported to CMS, 2019-2025
33 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $768 · 2021: $1,311 · 2022: $1,363 · 2023: $1,353 · 2024: $1,435 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Education: $99.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.29 |
| Education | $99.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,436.52 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,511.69 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $852.25 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $655.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.59 | 2019-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $391.47 | 2019-2025 | Linzess |
| Genzyme Corporation | $174.51 | 2023-2025 | |
| Celgene Corporation | $161.39 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $155.91 | 2020-2024 | Talicia |
| Boston Scientific Corporation | $141.38 | 2024-2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $129.76 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $126.41 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $100.54 | 2019-2024 | Dificid |
| Ardelyx, INC. | $99.17 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $96.87 | 2023-2025 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $83.19 | 2021-2024 | Endoflip |
| Nestle Healthcare Nutrition INC. | $76.90 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $72.61 | 2024-2025 | Zenpep |
| Organon LLC | $69.47 | 2024-2025 | Hadlima |
| Daiichi Sankyo INC. | $55.57 | 2019-2022 | |
| Gilead Sciences, INC. | $50.44 | 2019-2022 | |
| Ucb, INC. | $41.74 | 2019-2020 | |
| Qol Medical, LLC | $39.19 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $28.03 | 2021-2024 | |
| Alfasigma USA, INC. | $27.81 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $27.37 | 2020 | |
| Allergan, INC. | $26.03 | 2019-2020 | |
| Shionogi INC | $21.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.98 | 2024 | Bylvay |
| Janssen Pharmaceuticals, INC | $20.01 | 2023 | Xarelto |
| Orphalan INC | $15.74 | 2024 | Cuvrior |
| Mallinckrodt Hospital Products INC. | $14.78 | 2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $13.24 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herve Boucard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.